Latest R&D and Business News
- Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer’s Disease
- If approved, Dupixent would be the first biologic medicine available in the U.S. for these children
- Syndivia In-Licenses DARx Technology for 1-to-1 Linkage of Antibodies and Payloads for Preparation of New Classes of Biologics
- Blueberry Therapeutics receives clearance from the FDA to proceed with the clinical investigation of BB2603
- Researchers Present Positive Interim Data on Appili Therapeutics’ ATI-1701 Biodefense Program at 2020 ASM Biothreats
- Ikena Oncology Announces Dosing of First Patient in Phase 1 Study Evaluating IK-175 in Patients with Advanced Solid Tumors
- Clover Initiates Development of Recombinant Subunit-Trimer Vaccine for Wuhan Coronavirus (2019-nCoV)
- Avacta’s Proprietary TMAC Cancer Therapy Platform Demonstrates Successful Proof-of-Concept in Pre-Clinical Study
- Syros Announces First Patient Dosed in Phase 1 Clinical Trial of SY-5609, Its Highly Selective and Potent Oral CDK7 Inhibitor, in Patients with Select Solid Tumors
- Incyte Announces that the TRuE-AD2 Pivotal Trial of Ruxolitinib Cream Met its Primary Endpoint in Patients with Atopic Dermatitis
- US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes
- GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development